Association of Prenatal Tobacco Exposure Verified by Maternal Urinary Cotinine With Umbilical Cord Blood Lactate, Fetal Carboxyhemoglobin, and Early Neonatal Outcomes: A Prospective Single-Center Observational Study
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 126
- 主要终点
- Umbilical Cord Blood Lactate
研究概览
简要总结
Prenatal exposure to tobacco smoke, through either active maternal smoking or secondhand exposure, has been associated with impaired fetal oxygenation, metabolic stress, and adverse early neonatal outcomes. This prospective, single-center observational cohort study will objectively assess maternal tobacco exposure using cotinine measured in maternal urine and examine its association with early neonatal biochemical, metabolic, and clinical outcomes.
Consecutive eligible mother-newborn dyads will be recruited at a tertiary academic hospital after written informed consent is obtained. A clean-catch midstream maternal urine sample will be collected within 24 hours before delivery, preferably at admission to the delivery unit and before intravenous fluid administration, for quantitative cotinine and creatinine measurement. Maternal tobacco exposure will be assessed using the urinary cotinine concentration, the cotinine-to-creatinine ratio, and maternal self-reported smoking and secondhand smoke exposure. Based on prespecified biomarker thresholds and exposure history, participants will be classified as having active exposure, passive exposure, or no exposure. No experimental intervention will be administered.
Neonatal data will include umbilical cord blood gas parameters, including pH, pCO2, pO2, base excess, bicarbonate, lactate, and fetal carboxyhemoglobin (FCOHb). Birthweight, length, head circumference, Apgar scores, oxygen saturation, heart rate, and blood pressure will also be recorded. Routine laboratory measurements obtained during the early postnatal period will include complete blood count parameters, hematologic and inflammatory indices such as NLR and PLR, albumin, the albumin-to-lactate ratio, HDL, LDL, and other routinely available biochemical markers. Thyroid-stimulating hormone results from the national newborn screening program and newborn hearing screening results will be recorded. Postnatal weight loss and bilirubin measurements from routine follow-up visits will also be collected when available.
The primary objective is to determine whether increasing maternal urinary cotinine exposure is associated with higher umbilical cord blood lactate and FCOHb levels, indicating greater metabolic stress and impaired fetal oxygenation. Secondary objectives include evaluating associations with cord blood gas parameters, birthweight, early hematologic and biochemical indices, albumin and the albumin-to-lactate ratio, blood pressure, bilirubin levels, thyroid screening results, and hearing screening outcomes.
Maternal, obstetric, and perinatal variables, including maternal age, parity, gestational age, mode of delivery, smoking history, intrapartum factors, and relevant maternal comorbidities, will be recorded for adjusted analyses. Statistical analyses will include comparisons among the three exposure groups and multivariable regression models evaluating urinary cotinine both as a continuous measure and as a categorical exposure variable.
This study is designed to provide prospectively collected, biomarker-verified evidence regarding the relationship between maternal tobacco exposure and immediate neonatal metabolic, hematologic, and physiologic outcomes using measurements that are feasible within routine clinical care.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 0 Minutes 至 72 Hours(Child)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Pregnant individual expected to deliver a liveborn infant at the study hospital and providing written informed consent before delivery.
- •Singleton pregnancy with an anticipated gestational age of ≥35 completed weeks at delivery.
- •Maternal clean-catch urine sample obtainable within 24 hours before delivery, preferably at admission and before intravenous fluid administration, for urinary cotinine and creatinine measurement.
- •Availability of routine umbilical cord blood gas analysis at birth, including at minimum lactate, pH, and base excess, with fetal carboxyhemoglobin recorded when available.
- •Availability of routine neonatal clinical data, including birthweight, anthropometric measurements, Apgar scores, vital signs, and early postnatal assessments according to unit practice.
排除标准
- •Multiple gestation.
- •Major congenital anomaly, known chromosomal or genetic disorder, or major metabolic disease likely to affect neonatal adaptation or the study outcomes.
- •Emergency clinical circumstances in which obtaining informed consent or the maternal urine sample could delay or interfere with urgent maternal or neonatal care.
- •Inability to obtain an adequate maternal urine sample before delivery for cotinine and creatinine measurement.
- •Severe perinatal condition preventing acquisition or reliable interpretation of the primary outcome data, including major birth trauma or prolonged intensive care requirement.
- •Missing umbilical cord blood lactate measurement or other critical primary outcome data.
- •Previous enrollment of the same mother-newborn dyad.
研究组 & 干预措施
Active Prenatal Tobacco Exposure (Maternal Urinary Cotinine-Defined)
Mother-newborn dyads in whom the maternal urinary cotinine-to-creatinine ratio is consistent with active tobacco exposure according to the prespecified study threshold. Maternal self-reported smoking and secondhand smoke exposure will also be recorded as supportive exposure information.
Neonatal outcomes will include umbilical cord blood gas parameters, including pH, pCO2, pO2, base excess, bicarbonate, lactate, and fetal carboxyhemoglobin (FCOHb); birthweight and other anthropometric measurements; Apgar scores; oxygen saturation; heart rate; blood pressure; and routine laboratory measurements obtained during the early postnatal period. Laboratory variables will include complete blood count parameters, NLR, PLR, albumin, the albumin-to-lactate ratio, HDL, LDL, and other routinely available biochemical markers. Newborn screening TSH, hearing screening results, postnatal weight loss, and bilirubin measurements will also be recorded where available.
干预措施: Maternal Urinary Cotinine Assessment (Other)
Passive Prenatal Tobacco Exposure (Maternal Urinary Cotinine-Defined)
Mother-newborn dyads in whom the maternal urinary cotinine-to-creatinine ratio is detectable but below the active-exposure threshold and is consistent with passive prenatal tobacco exposure according to the prespecified study thresholds. Maternal self-reported smoking and secondhand smoke exposure will also be recorded as supportive exposure information.
The same neonatal biochemical, metabolic, physiologic, and clinical measurements will be collected as in the active-exposure and reference cohorts. No experimental intervention will be administered.
干预措施: Maternal Urinary Cotinine Assessment (Other)
No Prenatal Tobacco Exposure (Maternal Urinary Cotinine-Defined Reference Cohort)
Mother-newborn dyads in whom the maternal urinary cotinine-to-creatinine ratio is below the prespecified no-exposure threshold or below the analytical detection limit. Maternal smoking and secondhand smoke exposure history will also be recorded to assess agreement between biomarker-based and self-reported exposure classifications.
The same neonatal biochemical, metabolic, physiologic, and clinical measurements will be collected as in the exposed cohorts. No experimental intervention will be administered.
干预措施: Maternal Urinary Cotinine Assessment (Other)
结局指标
主要结局
Umbilical Cord Blood Lactate
时间窗: At birth (sample obtained within 10 minutes of delivery; analyzed within routine lab turnaround)
Umbilical cord blood lactate concentration measured using routine blood gas analysis. Lactate levels will be compared across maternal urinary cotinine-defined exposure groups (active, passive, and no exposure) and evaluated in multivariable regression models with adjustment for relevant maternal and perinatal factors. Unit of Measure: mmol/L.
Umbilical Cord Blood Lactate
时间窗: At birth (sample obtained within 10 minutes of delivery; analyzed within routine lab turnaround)
Cord blood lactate (mmol/L) measured per standard laboratory protocol. Primary analysis compares lactate across cotinine-defined exposure groups (active vs passive vs none) with multivariable adjustment (e.g., gestational age, mode of delivery). No extra blood drawn beyond routine cord sampling. Unit of Measure: mmol/L
次要结局
- Umbilical Cord Blood Base Excess (BE)(At birth (within 10 minutes))
- Fetal Carboxyhemoglobin (FCOHb)(At birth (same cord sample, routine CO-oximetry if available))
- Umbilical Cord Blood pH(At birth (within 10 minutes))
- Umbilical Cord Blood pH(At birth (within 10 minutes))
- Umbilical Cord Blood Base Excess (BE)(At birth (within 10 minutes))
- Fetal Carboxyhemoglobin (FCOHb)(At birth (same cord sample, routine CO-oximetry if available))
研究者
Berker Okay
MD - Pediatrician (Principal Investigator)
Haseki Training and Research Hospital
